221 related articles for article (PubMed ID: 18496571)
1. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.
Yang S; Cohen CJ; Peng PD; Zhao Y; Cassard L; Yu Z; Zheng Z; Jones S; Restifo NP; Rosenberg SA; Morgan RA
Gene Ther; 2008 Nov; 15(21):1411-23. PubMed ID: 18496571
[TBL] [Abstract][Full Text] [Related]
2. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.
Pouw N; Treffers-Westerlaken E; Kraan J; Wittink F; ten Hagen T; Verweij J; Debets R
Cancer Immunol Immunother; 2010 Jun; 59(6):921-31. PubMed ID: 20101507
[TBL] [Abstract][Full Text] [Related]
3. A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes.
Yang S; Karne NK; Goff SL; Black MA; Xu H; Bischof D; Cornetta K; Rosenberg SA; Morgan RA; Feldman SA
Hum Gene Ther Methods; 2012 Apr; 23(2):73-83. PubMed ID: 22515320
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy.
Wagner SN; Wagner C; Schultewolter T; Goos M
Cancer Immunol Immunother; 1997 Jun; 44(4):239-47. PubMed ID: 9222283
[TBL] [Abstract][Full Text] [Related]
5. CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.
Norell H; Zhang Y; McCracken J; Martins da Palma T; Lesher A; Liu Y; Roszkowski JJ; Temple A; Callender GG; Clay T; Orentas R; Guevara-Patiño J; Nishimura MI
Cancer Immunol Immunother; 2010 Jun; 59(6):851-62. PubMed ID: 20052466
[TBL] [Abstract][Full Text] [Related]
6. TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008.
Uckert W; Schumacher TN
Cancer Immunol Immunother; 2009 May; 58(5):809-22. PubMed ID: 19189103
[TBL] [Abstract][Full Text] [Related]
7. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.
Liu K; Rosenberg SA
J Immunol; 2001 Dec; 167(11):6356-65. PubMed ID: 11714800
[TBL] [Abstract][Full Text] [Related]
8. Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.
Frecha C; Lévy C; Cosset FL; Verhoeyen E
Mol Ther; 2010 Oct; 18(10):1748-57. PubMed ID: 20736930
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes.
Ikeda H; Shiku H
Cancer Immunol Immunother; 2015 Jul; 64(7):903-9. PubMed ID: 26041411
[TBL] [Abstract][Full Text] [Related]
10. A biomaterial platform for T cell-specific gene delivery.
Pandit S; Smith BE; Birnbaum ME; Brudno Y
Acta Biomater; 2024 Mar; 177():157-164. PubMed ID: 38364929
[TBL] [Abstract][Full Text] [Related]
11. Melanoma tumour-infiltrating T-lymphocyte therapy heralds the era of cell-based immunotherapies for solid tumours.
Talty R; Richmond R; Micevic G
Br J Dermatol; 2024 May; 190(6):779-781. PubMed ID: 38516835
[No Abstract] [Full Text] [Related]
12. Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform.
Amendola M; Passerini L; Pucci F; Gentner B; Bacchetta R; Naldini L
Mol Ther; 2009 Jun; 17(6):1039-52. PubMed ID: 19293777
[TBL] [Abstract][Full Text] [Related]
13. Induction of human blood group a antigen expression on mouse cells, using lentiviral gene transduction.
Fan X; Lang H; Zhou X; Zhang L; Yin R; Maciejko J; Giannitsos V; Motyka B; Medin JA; Platt JL; West LJ
Hum Gene Ther; 2010 Jul; 21(7):877-90. PubMed ID: 20163247
[TBL] [Abstract][Full Text] [Related]
14. Bioengineered viral vectors for targeting and killing prostate cancer cells.
Zhang KX; Jia W; Rennie PS
Bioeng Bugs; 2010; 1(2):92-6. PubMed ID: 21326934
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral vector followed by protein immunisation breaks tolerance against the self-antigen Her1 and results in lung cancer immunotherapy.
Alpizar YA; Karwacz K; Arce F; Yglesias Rivera A; Fernández LE; Collins MK; Sánchez Ramírez B
J Gene Med; 2012 Mar; 14(3):151-7. PubMed ID: 22262303
[TBL] [Abstract][Full Text] [Related]
16. Optimized peptide nanofibrils as efficient transduction enhancers for
Rauch-Wirth L; Renner A; Kaygisiz K; Weil T; Zimmermann L; Rodriguez-Alfonso AA; Schütz D; Wiese S; Ständker L; Weil T; Schmiedel D; Münch J
Front Immunol; 2023; 14():1270243. PubMed ID: 38022685
[TBL] [Abstract][Full Text] [Related]
17. Harnessing lentiviral vectors for in vivo gene therapy of liver metastases.
Giacca G; Naldini L; Squadrito ML
Clin Transl Med; 2024 Jan; 14(1):e1542. PubMed ID: 38230542
[No Abstract] [Full Text] [Related]
18. DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer.
Wang GP; Garrigue A; Ciuffi A; Ronen K; Leipzig J; Berry C; Lagresle-Peyrou C; Benjelloun F; Hacein-Bey-Abina S; Fischer A; Cavazzana-Calvo M; Bushman FD
Nucleic Acids Res; 2008 May; 36(9):e49. PubMed ID: 18411205
[TBL] [Abstract][Full Text] [Related]
19. Designer bugs as cancer drugs?
Sajjath SM; Gola A; Fuchs E
Science; 2023 Apr; 380(6641):132-133. PubMed ID: 37053342
[TBL] [Abstract][Full Text] [Related]
20. Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Jones S; Peng PD; Yang S; Hsu C; Cohen CJ; Zhao Y; Abad J; Zheng Z; Rosenberg SA; Morgan RA
Hum Gene Ther; 2009 Jun; 20(6):630-40. PubMed ID: 19265475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
